Altai Capital Managements Adds To Position In Vocus, Inc. (VOCS)

Rishi Bajaj, Toby Symonds and Steve Tesoriere are bullish on Vocus, Inc. (NASDAQ:VOCS). As reported in a recent filing with the Securities and Exchange Commission, their fund, Altai Capital, has increased its holding of the stock by a little under 1 million shares, taking it to 2.5 million shares. This new position accounts for 11.6% of the total number of Vocus shares outstanding and, given the current market price of $13.34 per share, Altai’s stake is worth approximately $32.8 million.


Ahmet Okumus is also keeping an eye on Vocus, Inc. (NASDAQ:VOCS). According to its latest 13F report, Okumus Fund Management, holds 4.9 million shares valued at $56 million, the largest position among the hedge funds we track. Jim Simons and his fund, Renaissance Technologies, also have a stake in this company, but have chosen to limit their exposure. During the previous quarter, Renaissance almost halved its position to 259,700 shares reportedly worth $3.0 million.

A provider of cloud marketing software, Vocus, Inc. (NASDAQ:VOCS) has a market cap of $288 million and does not pay a dividend. For the three months ending December 31, 2013, the company posted revenues of $47.4 million and a loss per share of $0.20. Market participants expect Vocus to generate revenues of $45.3 million and EPS of $0.07 for the current quarter. The stock has been in an uptrend since November and has advanced approximately 17% so far this year. It is trading at a forward Price to Earnings (P/E) ratio of 32.5x.

Altai Capital has recently increased its holding of RealD (NYSE:RLD) stock from 4.5 million to 4.8 million shares, which corresponds to 9.8% of the company’s common stock outstanding, and has initiated a new position in Wausau Paper Corp (NYSE:WPP), purchasing 2.6 million shares which account for 5.5% of the company’s total number of shares outstanding.

Disclosure: none.

Recommended reading:

Select Equity Group Raises Stake in Walter Investment Management (WAC)

Mark Stupfel’s Cortex Capital Management Is Bullish On These Stocks

Billionaire John Paulson and Jacob Gottlieb Boost Their Stakes in Enzymotec Ltd (ENZY)

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!